Home  |  Contact

UniProtKB/Swiss-Prot Q9H553: Variant p.Val68Gly

Alpha-1,3/1,6-mannosyltransferase ALG2
Gene: ALG2
Variant information

Variant position:  68
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Valine (V) to Glycine (G) at position 68 (V68G, p.Val68Gly).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (V) to glycine (G)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMS14; shows severely reduced expression of the mutant protein.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  68
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  416
The length of the canonical sequence.

Location on the sequence:   KIWTAHYDPGHCFAESRELP  V RCAGDWLPRGLGWGGRGAAV
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 416 Alpha-1,3/1,6-mannosyltransferase ALG2
Alternative sequence 1 – 91 Missing. In isoform 2.


Literature citations

Congenital myasthenic syndromes due to mutations in ALG2 and ALG14.
Cossins J.; Belaya K.; Hicks D.; Salih M.A.; Finlayson S.; Carboni N.; Liu W.W.; Maxwell S.; Zoltowska K.; Farsani G.T.; Laval S.; Seidhamed M.Z.; Donnelly P.; Bentley D.; McGowan S.J.; Muller J.; Palace J.; Lochmuller H.; Beeson D.; Donnelly P.; Bell J.; Bentley D.; McVean G.; Ratcfliffe P.; Taylor J.; Wilkie A.; Donnelly P.; Broxholme J.; Buck D.; Cazier J.B.; Cornall R.; Gregory L.; Knight J.; Lunter G.; McVean G.; Taylor J.; Tomlinson I.; Wilkie A.; Buck D.; Allan C.; Attar M.; Green A.; Gregory L.; Humphray S.; Kingsbury Z.; Lamble S.; Lonie L.; Pagnamenta A.; Piazza P.; Polanco G.; Trebes A.; McVean G.; Donnelly P.; Cazier J.B.; Broxholme J.; Copley R.; Fiddy S.; Grocock R.; Hatton E.; Holmes C.; Hughes L.; Humburg P.; Kanapin A.; Lise S.; Lunter G.; Martin H.; Murray L.; McCarthy D.; Rimmer A.; Sahgal N.; Wright B.; Yau C.;
Brain 136:944-956(2013)
Cited for: INVOLVEMENT IN CMS14; VARIANT CMS14 GLY-68; CHARACTERIZATION OF VARIANT CMS14 GLY-68;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.